BioPharma Dive February 16, 2024
Ben Fidler

The FDA issued a partial hold on four tests of magrolimab in solid tumors, as Gilead evaluates the program’s future.

Gilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal following a new setback the company reported late Thursday.

In a statement, Gilead said it paused enrollment in four mid-stage trials of the drug, known as magrolimab, in different types of solid tumors. The Food and Drug Administration subsequently ordered a partial hold on these trials. The suspension also applies to investigator-run tests of magrolimab, the company said.

Gilead didn’t specify why it stopped recruiting study participants. However, one week ago, the company disclosed a regimen involving magrolimab was associated with an increased risk of...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article